¿ CombiMatrix Corp., of Burlingame, Calif., completed a $4 million private equity financing. The company is developing a biochip system, with the first application expected in genomics. It also has programs in proteomics and combinatorial chemistry.
¿ Cytogen Corp., of Princeton, N.J., formed an alliance with Bostwick Laboratories, of Richmond, Va., to develop a nationwide service to stain tissues for prostate specific membrane antigen (PSMA), a transmembrane protein that is found associated with cancerous prostate cells. PSMA is the target antigen for the monoclonal antibody, 7E11, which is used in Cytogen's ProstaScint prostate cancer imaging agent.
¿ Dendreon Corp., of Seattle, received approval to market DACS SC, a device used to prepare autologous hematopoietic stem cells from blood. The product is used to isolate cells for transplantation in cancer patients following chemotherapy or radiation treatment.
¿ Genomica Corp., of Boulder, Colo., licensed its Discovery Manager software and reference database to the Parke-Davis division of Warner-Lambert Co., of Morris Plains, N.J. Discovery Manager offers visualization and scientific analysis tools, project management and a database of genetic information. Terms were not disclosed.
¿ PE Biosystems, of San Jose, Calif., Genomica Corp., of Boulder, Colo., and Oxagen Ltd., of Abingdon, UK, signed an agreement to develop advanced software for high-throughput genotyping. The agreement leverages Oxagen's expertise in high-throughput genotyping and functional analysis with Genomica's analytical software tools and PE Biosystems' instrumentation systems and unified software for drug discovery. Terms were not released.
¿ SangStat Medical Corp., of Freemont, Calif., said Abbott Laboratories, of Abbott Park, Ill., completed its $14 million equity investment in SangStat related to their multiyear co-promotion, distribution and research agreement for SangCya (cyclosporine oral solution). (See BioWorld Today, May 11, 1999, p. 1.)
¿ The Liposome Co., of Princeton, N.J., said the European Medicines Evaluation Agency accepted the filing of Evacet (liposomal doxorubicin) for the treatment of metastatic breast cancer, either alone or in combination with cyclophosphamide. The company said regulatory approval is expected in the third quarter 2000. The product currently is under review with the FDA.